Cericlamine

Cericlamine
Clinical data
Other names	JO-1017
Routes of; administration	Oral
ATC code	None;
Pharmacokinetic data
Elimination half-life	8 hours
Identifiers
	IUPAC name 3-(3,4-Dichlorophenyl)-2-(dimethylamino)-2-methylpropan-1-ol;
CAS Number	112922-55-1;
PubChem CID	131074;
ChemSpider	115890;
UNII	VES82D23IB;
CompTox Dashboard (EPA)	DTXSID00869558 ;
Chemical and physical data
Formula	C12H17Cl2NO
Molar mass	262.17 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(CC1=CC(=C(C=C1)Cl)Cl)(CO)N(C)C;
	InChI InChI=1S/C12H17Cl2NO/c1-12(8-16,15(2)3)7-9-4-5-10(13)11(14)6-9/h4-6,16H,7-8H2,1-3H3; Key:FWYRGHMKHZXXQX-UHFFFAOYSA-N;

Cericlamine (INN; developmental code JO-1017) is a potent and moderately selective serotonin reuptake inhibitor (SSRI) of the amphetamine family (specifically, a derivative of phentermine, and closely related to chlorphentermine, a highly selective serotonin releasing agent) that was investigated as an antidepressant for the treatment of depression, anxiety disorders, and anorexia nervosa by Jouveinal but did not complete development and was never marketed.^[1]^[2]^[3]^[4] It reached phase III clinical trials in 1996 before development was discontinued in 1999.^[5]

Quick Facts Clinical data, Other names ...

According to Czech scientists, cericlamine is claimed to be part of a highly advanced “fifth generation” of antidepressants as was venlafaxine.^[6]

The daily dosage was reported to be 300mg.^[1]

See also